樂觀
$55.23
情境價格
$63.440
+3.369 (+5.31%)收盤時
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It manufactures machined sub-assemblies and also produces parts and assemblies for aerospace and defense systems.
Currently, Pro-Dex Inc (PDEX) is trading at $57.65, which is significantly below its 52-week high of $77.00, indicating potential for recovery. However, the RSI is at 29.815, suggesting it is in oversold territory, which could lead to a rebound. The forward P/E ratio is 19.12, indicating that the stock may be overvalued based on future earnings expectations. The company reported a net income of $13.66 million for FY 2026, a 52% increase from the previous year, which is a positive sign for long-term investors. However, the stock has seen a 4.96% decline over the past five days, which reflects short-term volatility. Given these factors, it may be prudent to hold rather than buy at this moment, as the stock could stabilize before making a more informed investment decision.
Ascendiant Capital
$52
2024-11-11
Ascendiant Capital
2024-11-11
目標價
$52
Ascendiant Capital
$30
2024-09-09
Ascendiant Capital
2024-09-09
目標價
$30
情境價格取自當年最後一個月度預測區間。機率為固定的模型權重(25 / 50 / 25),不構成保證。

Pro-Dex Reports 16% Revenue Growth in FY 2026

Vivos Therapeutics Reports Better-Than-Expected Quarterly Loss

Pro-Dex Completes Acquisition of Advanced Precision Machining LLC

Pro-Dex Reports Q2 Earnings with Revenue of $1.9M

Pro-Dex (PDEX) Extends Major Customer Contract by Three Years, Anticipates Revenue Growth
Pro-Dex, Inc. specializes in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used primarily in the orthopedic, thoracic, and maxocranial facial markets. The Company has patented adoptive torque-limiting software and sealing solutions, which appeal to its customers, primarily medical device distributors. It also manufactures and sells rotary air motors to a range of industries. The Company’s medical device products utilize designs developed by it primarily under development and supply agreements and are machined in its Irvine, California facility, and assembled in its Tustin, California facility, as are its rotary air motors. Its medical device products are sold primarily to original equipment manufacturers and its air motors are sold primarily to a range of distributors and end users. It manufactures machined sub-assemblies and also produces parts and assemblies for aerospace and defense systems. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).
Currently, Pro-Dex Inc (PDEX) is trading at $57.65, which is significantly below its 52-week high of $77.00, indicating potential for recovery. However, the RSI is at 29.815, suggesting it is in oversold territory, which could lead to a rebound. The forward P/E ratio is 19.12, indicating that the stock may be overvalued based on future earnings expectations. The company reported a net income of $13.66 million for FY 2026, a 52% increase from the previous year, which is a positive sign for long-term investors. However, the stock has seen a 4.96% decline over the past five days, which reflects short-term volatility. Given these factors, it may be prudent to hold rather than buy at this moment, as the stock could stabilize before making a more informed investment decision.
1 analysts cover PDEX: 1 rate it Buy, 0 Hold and 0 Sell.
暫無貼文
註冊或登入後參與討論本頁僅供研究參考,不構成投資建議。模型可能出錯。過往表現不代表未來結果。